1. Catalogs
  2. HAEMONETICS
  3. Introducing TEG 6s - White Paper

Introducing TEG 6s - White Paper

Introducing TEG 6s - White Paper
1 / 35 PagesView full catalog

Introducing TEG 6s - White Paper

Product catalog summary
Introduction
The document introduces the TEG 6s device, an innovative tool for viscoelastic hemostatic assays (VHAs) using an all-in-one cartridge. The TEG system provides real-time analysis of the viscoelastic properties of hemostasis, enabling personalized therapy and aiding clinicians in making informed treatment decisions.
Benefits of TEG
TEG is advantageous in various medical scenarios, such as reducing blood product usage in cardiac surgery, stratifying bleeding risk for patients on antiplatelet medications, predicting massive transfusion needs in trauma patients, and improving pharmaceutical use in ICU patients.
TEG 6s Technology
The TEG 6s improves upon the TEG 5000 with a more precise and repeatable design, measuring viscoelastic properties with enhanced precision. It uses microfluidic cartridges for assays, allowing for smaller sample sizes and reducing sensitivity to external vibrations.
Hemostasis and TEG
TEG provides a comprehensive analysis of the coagulation process, assessing coagulation in whole blood, unlike conventional coagulation tests (CCTs) which are limited to plasma samples.
TEG Test Suite
The TEG 6s can run up to four assays simultaneously using microfluidic cartridges, simplifying the process and improving quality assurance. The Global Hemostasis Cartridge and Platelet Mapping Cartridge offer detailed insights into coagulation status.
Global Assays Concept
TEG 6s allows multiple assays from a single blood sample, providing a detailed clinical picture of hemostasis in as little as 10 minutes, optimizing patient management.
TEG 6s Platform Overview
The platform automates and standardizes coagulation testing, ensuring accuracy and simplifying procedures. Key parameters provide insights into clot initiation, fibrinogen contribution, and overall clot strength.
Clinical Outcomes and Cost-Effectiveness
TEG improves patient outcomes and reduces costs by individualizing coagulation management, reducing inappropriate blood transfusions, and stratifying patients by bleeding risk. It is beneficial in settings like liver transplants and cardiovascular surgery.
Networked Solutions
The TEG 6s analyzer can be networked via TEG Manager, allowing centralized data access and remote viewing of test results, facilitating near-patient testing and informed treatment decisions.
Overview of TEG Manager and TEG 6s
TEG Manager manages and analyzes test results from TEG 6s analyzers, consisting of TEG Viewer for remote access and Device Manager for administration. It integrates with hospital networks for efficient data management.
Comparison of TEG 6s and TEG 5000
A study showed strong correlations between TEG 6s and TEG 5000, indicating that TEG 6s can effectively replace or complement TEG 5000.
Analytical Performance of TEG 6s
The analytical performance of TEG 6s was validated through a multisite study, confirming its precision and repeatability.
Conclusion
TEG 6s offers a rapid, comprehensive, and accurate assessment of coagulation status, simplifying the testing process with automated systems and providing reliable results with minimal user intervention.
Overview of TEG 6s and Its Clinical Applications
TEG 6s plays a crucial role in patient blood management, reducing blood product usage, ensuring appropriate pharmaceutical use, and minimizing hospital stay costs.
TEG 6s Specifications
TEG 6s is capable of near-patient testing to predict bleeding and thrombosis risks, allowing for personalized hemostatic therapy.
Clinical Applications
TEG-based transfusion algorithms are essential in managing blood transfusions, particularly in surgical settings.
Research and References
The document includes references supporting the efficacy of TEG in various clinical scenarios, demonstrating its role in improving patient outcomes.
Conclusion
TEG 6s is a valuable tool in modern medicine, offering real-time insights into a patient's coagulation status, aiding in targeted and efficient hemostatic interventions.
See more

Catalog excerpts

Introducing TEG 6s - White Paper-1

Introducing WHITE PAPER This white paper presents the TEG 6s device, a revolutionary approach to viscoelastic hemostatic assays (VHAs) science by the introduction of an innovative, all-in-one cartridge. The TEG system is a real-time analyzer of whole blood measuring the viscoelastic properties of the hemostasis process and allowing for individualized goal-directed therapy. It provides rapid, comprehensive and accurate identification of an individual’s hemostasis condition, in a laboratory or in the context of near-patient testing, which allows clinicians to drive personalized, clinically and economically sound treatment and monitoring decisions. The demonstrated benefits of using TEG: In cardiac surgery, TEG allows a reduction in blood product usage by providing clinicians with information to help determine which specific blood products are needed to stop bleeding, and accurately identifies the need for re-operations by ruling out a coagulopathic cause of bleeding. For patients on antiplatelet medications, TEG helps to stratify bleeding risk and reduce time to schedule coronary artery bypass graft (CABG) surgery and length of stay. TEG is more predictive than conventional coagulation tests (CCTs) in anticipating massive transfusion, delivers results faster for trauma physicians and guides specific blood products and ’high risk’ drugs to stop bleeding in trauma patients and predicts those at high risk of pulmonary embolism (PE). (3-8) TEG helps to stratify risk of thrombotic events by helping clinicians determine which patients are at risk of thrombotic events and to determine the effectiveness of P2Y12 agonists. TEG helps to stratify risk of deep vein thrombosis and PE in ICU patients and improves adequate use of expensive pharmaceuticals (rFVIIa, fibrinogen).

 Open the catalog to page 1
Introducing TEG 6s - White Paper-2

■ The TEG 6s technology innovation. TEG 6s measures the same viscoelastic properties as the TEG 5000. The new measurement technique associated with microfluidic sample preparation can Pe appreciated by its simplicity of use as well as the precision and repeatability of its results. Same ^^^^^^H Simple Assess same physical property/results THE Blood Management Company

 Open the catalog to page 2
Introducing TEG 6s - White Paper-3

Coagulation is a complex physiological process. The cell-based model of hemostasis provides a valuable framework for explaining the complex physiological process of coagulation. The model includes three phases: initiation, amplification and propagation (Figure 1).(1) Figure 1. Cell-based model of hemostasis.1 [Reproduced from Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost 2001;85:958–65. Copyright 2015 with permission from Schattauer] The initiation phase involves activation of several coagulation factors via tissue factor. During the amplification phase, platelets...

 Open the catalog to page 3
Introducing TEG 6s - White Paper-4

What are viscoelastic hemostatic assays (VHAs)? VHAs are performed to assess coagulation in a sample of whole blood. Reagents are added principally to trigger coagulation and, in some VHAs, to block or stimulate the effects of certain constituents. In the TEG 5000 device, the blood is contained within a cup and a stationary pin is immersed in the blood (Figure 2A).(2) The cup rotates left and right in an oscillatory motion at a set speed through an arc of 4°45’. As the clot starts to form, it begins to bind to the cup and pin causing the pin to oscillate with the cup (Figure 2A). The rate with...

 Open the catalog to page 4
Introducing TEG 6s - White Paper-5

α angle (in °) is the angle formed by the slope of a tangent line from the tracing at the midpoint between the R and the K time. The K and α angle parameters reflect the rate of clot formation or the cleavage of fibrinogen into fibrin mediated by thrombin. LY30 (%) is the percentage reduction in amplitude 30 minutes after reaching MA. After the clot has formed, it is degraded by fibrinolytic factors within the blood and the amplitude decreases over time. By measuring the extent/speed of amplitude reduction, clot lysis can be assessed. Figure 2. The principles by which TEG functions. A. Diagram...

 Open the catalog to page 5
Introducing TEG 6s - White Paper-6

Importantly, TEG results are usually available more quickly than CCTs. In one study, RapidTEG results were available within 5–15 minutes (depending on the parameter), compared with 48 minutes for CCTs (p<0.001).(5) This can increase the speed with which appropriate hemostatic therapy is administered and, potentially, improve patient outcomes including increased survival.(7) Through TEG, the TEG PlateletMapping assay enables platelet function to be assessed. Therefore, TEG analysis may be compared with methods specifically designed for monitoring platelet function. Light transmittance aggregometry...

 Open the catalog to page 6
Introducing TEG 6s - White Paper-7

2. The TEG Test Suite CLINICAL VALUES Building upon the TEG 5000, up to four assays can be run simultaneously on the TEG 6s. This is achieved by using one of the two microfluidics cartridges available (described below), both prepackaged with all the required reagents. Global hemostasis cartridge (CM citrated) Kaolin TEG (CK). The standard TEG assay, which uses kaolin for activation of coagulation. Kaolin activation is classically described as intrinsic pathway activation, but the cell-based model of coagulation has rendered this terminology obsolete. The hemostasis profile resulting from kaolin...

 Open the catalog to page 7
Introducing TEG 6s - White Paper-8

Functional Fibrinogen assay to pinpoint fibrinogen or platelet deficiency, and the impact of the ratio of platelets and fibrin to the resulting clot strength. TEG Functional Fibrinogen (CFF). Tissue factor is used for coagulation activation that would be classically described as extrinsic, with platelet function inhibited by a GPIIb/IIIa inhibitor such that the resulting contribution of the functional fibrinogen to clot strength is exhibited. By subtracting this functional fibrinogen contribution from the overall clot strength, the specific contribution of platelet function is extrapolated. Clinical...

 Open the catalog to page 8
Introducing TEG 6s - White Paper-9

increased thrombosis risk. In trauma, ADP responsiveness has been correlated with a patient’s need for transfusion. TEG 6s cartridges Simple. The assays described above are performed on TEG 6s using one of two microfluidic cartridges (see section 5), each of which has four analysis channels utilizing minimal blood volumes of 300 μL for all four channels (Table 1). Cartridge Sample type Kaolin TEG with heparinase (HKH) Platelet mapping Kaolin TEG with heparinase (CKH) Global hemostasis AA Table 1. Configuration of TEG 6s cartridges. The TEG 6s cartridges enable multiple assays to be run automatically...

 Open the catalog to page 9

All HAEMONETICS catalogs and technical brochures

  1. NexSys PCS

    6  Pages

  2. PCS 2

    4  Pages

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.